Buradasınız

Anasayfa » Content

Erdosteinin Diyabetik Ratlarda Böbrek Hasarı Üzerine Koruyucu Etkisi

The Protective Effect of Erdostein on Renal Injury in Diabetic Rats

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2010
DOI: 
DOI 10.5262/tndt.2010.1003.01

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Objectives : Oxidative stress plays a role in the pathogenesis of diabetic nephropathy. It has been reported in many studies that antioxidant therapy may decrease complications related to diabetes mellitus. We aimed to evaluate the protective effects of erdostein on diabetic renal injury in diabetic rats. MA TERIAL and Metho ds: Thirty rats were randomly divided into 5 experimental groups (Group 1: control, group 2: erdostein, group 3: alloxan, group 4: alloxan+erdostein, and group 5: alloxan+insulin, n=6 each). Rats were made diabetic using alloxan injection intraperiteonally. Erdostein (10 mg/kg/day) orally and insulin two times a day (3 g/kg) intraperitoneally were administered for four weeks. All rats were then sacrificed and kidney histopathological examinations were performed by light microscopy. Res ults : The diabetic rats had diabetic nephropathic changes in the kidney on histological examination but the rats treated with erdostein showed significantly less histopathological changes, similar to the control group compared with the diabetic rats not treated with erdostein (p<0.05). The histopathological changes in insulin-treated rats were significantly less than the diabetic rats (p<0.05). The rats treated with erdostein had histopathological changes similar to insulin-treated rats (p>0.05). Conclusio n: Based on the present data, we conclude that erdostein may show protective effects on renal injury due to diabetes mellitus.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Diyabetik nefropati patogenezinde oksidatif stres rol oynamaktadır. Birçok çalışmada antioksidan kullanımının diyabetik komplikasyonları azaltabileceği rapor edilmiştir. Bu çalışmada ratlarda diyabete bağlı gelişen böbrek hasarı üzerine erdosteinin koruyucu etkilerini gözlemlemek amaçlanmıştır. GEREÇ ve Yönte mLER: Otuz adet rat rastgele 5 deneysel gruba ayrıldı (Grup 1: kontrol, Grup 2: erdostein verilen grup, Grup 3; alloksan verilen grup, Grup 4: alloksan+erdostein verilen grup ve Grup 5: İnsülin+alloksan verilen grup, (her grupta n=6). Ratlar %0,9’luk sodyum klorürde çözünmüş alloksanın intraperitoneal enjeksiyonuyla diyabetik hale getirildi. Dört hafta boyunca erdostein (10 mg/kg/gün) oral yolla ve insülin günde 2 kez 3 g/kg dozunda intraperitoneal enjeksiyonla uygulandı. Sonrasında fareler kesildi. Işık mikroskopisi ile böbrekte histopatolojik değerlendirme yapıldı. Bulgular: Diyabet geliştirilen ratlarda belirgin diyabetik nefropatiye ait değişiklikler görülürken, erdostein tedavisi alan grup, almayan grupla karşılaştırıldığında histopatolojik değişiklikler anlamlı olarak daha az oranda görüldü (p<0.05). İnsülin alan ratlarda histolojik değişiklikler tedavisiz diyabetik gruba göre anlamlı olarak daha az gözlendi (p<0.05). Erdostein grubunda görülen histopatolojik değişiklikler insülin tedavisi alan ratlara benzerdi (p>0.05). Sonuç: Bu çalışmada, diyabette böbrekte oluşan hasar üzerine erdosteinin koruyucu etkisi olabileceğini gözlemledik
FULL TEXT (PDF): 
PDF icon arastrmx_172977_19_pp_157-161.pdf
  • 3
157-161
  • Turkish

REFERENCES

References: 

1. Kakkar R, Kalra J, Mantha S, Prasad K: Lipid peroxidation and
activity of antioxidant enzymes in diabetic rats. Mol Cell Biochem
1995; 151(2):113-119
2. Dechant K, Noble S: Erdosteine. Drugs 1996; 52(6):875-881
3. Braga P, Dal Sasso M, Zuccotti T: Assessment of the antioxidant
activity of the SH metabolite I of erdosteine on human neutrophil
oxidative bursts. Arzneimittelforschung 2000; 50(8):739-746
4. Biagi G, Fregnan G, Gazzani G, Vandoni G: Erdosteine protection
from cigarette smoke-induced loss of alpha 1-antitrypsin activity in
rat lungs. Int J Clin Pharmacol Ther Toxicol 1989; 27(5): 235-237
5. Inglesi M, Nicola M, Fregnan G, Bradamante S, Pagani G:
Synthesis and free radical scavenging properties of the enantiomers
of erdosteine. Farmaco 1994; 40(11):703-708
6. Yildirim Z, Sogut S, Odaci E, Iraz M, Ozyurt H, Kotuk M, Akyol
O: Oral erdosteine administration attenuates cisplatin-induced renal
tubular damage in rats. Pharmacol Res 2003; 47(2):149-156
7. Fadillioglu E, Yilmaz H, Erdogan H, Sogut S: The activities of
tissue xanthine oxidase and adenosine deaminase and the levels
of hydroxyproline and nitric oxide in rat hearts subjected to
doxorubicin: Protective effect of erdosteine. Toxicology 2003;
191(2-3):153-158
8. Fadillioğlu E, Erdoğan H, Söğüt S, Kuku I: Protective effects of
erdosteine against doxorubicin-induced cardiomyopathy in rats. J
Appl Toxicol 2003 200; 23(1):71-74
9. Traisman H, Greenwood R: A comparative clinical evaluation of a
new proprietary method for urine testing in juvenile diabetics. Clin
Pediatr (Phila) 1973; 12(6):357-359
10. Bora P, Srivastava L, Bhatt SD: Metabolic and histopathological
effects of streptozotocin induced diabetes in rats: effect of
propranolol and insulin. Indian J Exp Biol 1985; 23(1):23-26
11. Gruden G, Perin P, Camussi G: Insight on the pathogenesis of
diabetic nephropathy from the study of podocyte and mesangial cell
biology. Curr Diabetes Rev 2005; 1(1):27-40
12. Vardı N IM, Oztürk F, Ucar M, Gül M, Esrefoğlu M, Otlu A:
Deneysel diyabetin sıçan böbreklerinde meydana getirdiği histolojik
değişiklikler üzerine melatoninin iyileştirici etkileri. İnönü Üniv
Tıp Fak Dergisi 2005; 12:145-152
13. Geoffroy K, Troncy L, Wiernsperger N, Lagarde M, El Bawab S:
Glomerular proliferation during early stages of diabetic nephropathy
is associated with local increase of sphingosine-1-phosphate levels.
FEBS Lett 2005; 579(5):1249-1254
14. Yagmurca M, Fadillioglu E, Erdogan H, Ucar M, Sogut S, Irmak
MK: Erdosteine prevents doxorubicin-induced cardiotoxicity in
rats. Pharmacol Res 2003; 48(4):377-382
15. Ozyurt H, Yildirim Z, Kotuk M, Yilmaz HR, Yağmurca M, Iraz
M, Söğüt S, Gergerlioglu S: Cisplatin-induced acute renal failure
is ameliorated by erdosteine in a dose-dependent manner. J Appl
Toxicol 2004; 24(4):269-275
16. Erdogan H, Fadillioglu E, Yagmurca M, Uçar M, Irmak MK: Protein
oxidation and lipid peroxidation after renal ischemia-reperfusion
injury: protective effects of erdosteine and N-acetylcysteine. Urol
Res 2006; 34(1):41-46
17. Gurel A, Armutcu F, Cihan A, Numanoglu K, Unalacak M:
Erdosteine improves oxidative damage in a rat model of renal
ischemia-reperfusion injury. Eur Surg Res 2004; 36(4):206-209
18. Sakurai K, Katoh M, Someno K, Fujimoto Y: Apoptosis and
mitochondrial damage in INS-1 cells treated with alloxan. Biol
Pharm Bull 2001; 24(8):876-882
19. Sabu M, Smitha K, Kuttan R: Anti-diabetic activity of green
tea polyphenols and their role in reducing oxidative stress in
experimental diabetes. J Ethnopharmacol 2002; 83(1-2):109-116
20. Roy S, Sehgal R, Padhy B, Kumar VL. Antioxidant and protective
effect of latex of Calotropis procera against alloxan-induced
diabetes in rats. J Ethnopharmacol 2005; 102(3):470-473
21. Sepici-Dincel A, Açikgöz S, Cevik C, Sengelen M, Yeşilada E:
Effects of in vivo antioxidant enzyme activities of myrtle oil in
normoglycaemic and alloxan diabetic rabbits. J Ethnopharmacol
2007; 110(3):498-503
22. Tunc T, Uysal B, Atabek C, Kesik V, Caliskan B, Oztas E, Ersoz
N, Oter S, Guven A: Erdosteine and ebselen as useful agents in
intestinal ischemia/reperfusion injury. J Surg Res 2009; 155(2):
210-216

Thank you for copying data from http://www.arastirmax.com